These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17875197)

  • 1. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
    Gumbs PD; Verschuren WM; Souverein PC; Mantel-Teeuwisse AK; de Wit GA; de Boer A; Klungel OH
    Br J Clin Pharmacol; 2007 Nov; 64(5):680-5. PubMed ID: 17875197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic substitution of antihypertensive drugs: does it affect adherence?
    Van Wijk BL; Klungel OH; Heerdink ER; de Boer A
    Ann Pharmacother; 2006 Jan; 40(1):15-20. PubMed ID: 16303985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
    Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM
    Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical review: impact of statin substitution policies on patient outcomes.
    Atar D; Carmena R; Clemmensen P; K-Laflamme A; Wassmann S; Lansberg P; Hobbs R
    Ann Med; 2009; 41(4):242-56. PubMed ID: 19191052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
    Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
    Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
    Tilson L; Bennett K; Barry M
    Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
    Ol'binskaia LI; Danilogorskaia IuA
    Ter Arkh; 2003; 75(12):47-50. PubMed ID: 14959470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the assessment of prescribing: use of a 'substitution index'.
    Kunisawa S; Otsubo T; Lee J; Imanaka Y
    J Health Serv Res Policy; 2013 Jul; 18(3):138-43. PubMed ID: 23595576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
    Tilson L; McGowan B; Ryan M; Barry M
    Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 17. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia.
    Kalisch LM; Roughead EE; Gilbert AL
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):620-5. PubMed ID: 18324613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Generic substitution' in New Jersey, 1979-87.
    Culkin TT; Mendell S
    Am Pharm; 1989 Feb; NS29(2):25-30. PubMed ID: 2648782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug use review matters.
    Mueting M
    Nebr Nurse; 2007; 40(3):28. PubMed ID: 17915614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.